AR076177A1 - MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL - Google Patents

MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL

Info

Publication number
AR076177A1
AR076177A1 ARP100101094A ARP100101094A AR076177A1 AR 076177 A1 AR076177 A1 AR 076177A1 AR P100101094 A ARP100101094 A AR P100101094A AR P100101094 A ARP100101094 A AR P100101094A AR 076177 A1 AR076177 A1 AR 076177A1
Authority
AR
Argentina
Prior art keywords
oral cavity
condition
matrix metalloproteinases
expression
positive control
Prior art date
Application number
ARP100101094A
Other languages
English (en)
Spanish (es)
Inventor
Virginia Barnes
Harsh M Trivedi
Wei Wang
Tao Xu
Emi Shimizu
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42328354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of AR076177A1 publication Critical patent/AR076177A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP100101094A 2009-04-01 2010-03-31 MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL AR076177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16568509P 2009-04-01 2009-04-01

Publications (1)

Publication Number Publication Date
AR076177A1 true AR076177A1 (es) 2011-05-26

Family

ID=42328354

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101094A AR076177A1 (es) 2009-04-01 2010-03-31 MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL

Country Status (19)

Country Link
US (1) US8637266B2 (enExample)
EP (1) EP2414838B1 (enExample)
JP (1) JP5330596B2 (enExample)
CN (1) CN102365550B (enExample)
AR (1) AR076177A1 (enExample)
AU (1) AU2010232590B2 (enExample)
BR (1) BRPI1013185A2 (enExample)
CA (1) CA2757317C (enExample)
CO (1) CO6420374A2 (enExample)
DK (1) DK2414838T3 (enExample)
ES (1) ES2432864T3 (enExample)
MX (1) MX2011008438A (enExample)
MY (1) MY158406A (enExample)
PL (1) PL2414838T3 (enExample)
RU (1) RU2524629C2 (enExample)
SG (1) SG173487A1 (enExample)
TW (1) TWI405565B (enExample)
WO (1) WO2010115031A1 (enExample)
ZA (1) ZA201106054B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101745067B1 (ko) * 2014-12-31 2017-06-12 서울대학교산학협력단 치주질환 예측 시스템 및 이를 이용한 치주질환 예측 방법
KR102098624B1 (ko) * 2019-09-20 2020-04-08 서울대학교산학협력단 타액 mmp-9 및 il-8를 이용한 치주염 예측 시스템 및 이를 이용한 치주염 예측 방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538230A (en) 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US4358437A (en) 1978-11-29 1982-11-09 Beecham Group Limited Compositions
US5032386A (en) 1988-12-29 1991-07-16 Colgate-Palmolive Company Antiplaque antibacterial oral composition
US5288480A (en) 1987-01-30 1994-02-22 Colgate-Palmolive Co. Antiplaque antibacterial oral composition
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
GB9117140D0 (en) 1991-08-08 1991-09-25 Unilever Plc Treatment of periodontitis
DE4226043A1 (de) 1992-08-06 1994-02-10 Haarmann & Reimer Gmbh Mittel mit physiologischem Kühleffekt und für diese Mittel geeignete wirksame Verbindungen
US5756361A (en) * 1992-12-17 1998-05-26 Metra Biosystems, Inc. Screening method for periodontal disease
CA2176237A1 (en) 1993-11-10 1995-05-18 Richard P. Darveau Treatment of bacterially-induced inflammatory diseases
FI98961C (fi) * 1994-08-26 1997-09-10 Medix Biochemica Ab Oy Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi
US5578295A (en) 1995-04-28 1996-11-26 The Procter & Gamble Company Oral care compositions comprising certain substituted diphenyl ethers
EP0935454B1 (de) 1996-06-12 2001-08-22 Cognis Deutschland GmbH Kosmetische und/oder pharmazeutische zubereitungen
US5998487A (en) * 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
JP3763075B2 (ja) * 1998-04-24 2006-04-05 サンスター株式会社 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物
FR2794457B1 (fr) 1999-06-01 2001-08-10 Oreal Derives carbonates de retinol, procede de preparation et utilisations
US6165447A (en) * 1999-06-15 2000-12-26 Colgate-Palmolive Company Synergistic antibacterial combination
WO2001048481A1 (en) 1999-12-03 2001-07-05 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
GB0001704D0 (en) 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
WO2001078652A2 (en) 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6500409B1 (en) 2000-05-10 2002-12-31 Colgate Palmolive Company Synergistic antiplaque/antigingivitis oral composition
DE10059584A1 (de) 2000-11-30 2002-06-06 Beiersdorf Ag Kosmetische oder dermatologische getränkte Tücher
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
AU2003249531A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
US7005225B2 (en) 2002-11-12 2006-02-28 Samsung Electronics Company Organosol including amphipathic copolymeric binder having crystalline material, and use of the organosol to make dry tones for electrographic applications
TW200902047A (en) 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
GB2401865A (en) 2003-05-22 2004-11-24 Givaudan Sa Antibacterial and antifungal glycerol monocarbonates
WO2005039504A2 (en) 2003-10-24 2005-05-06 Eisai Co., Ltd. Compounds and methods for treating toll-like receptor 2-related diseases and conditions
US20070212686A1 (en) 2003-12-03 2007-09-13 Whitehead Institute For Biomedical Research Use Of T-Cadherin As A Target
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
JP4662043B2 (ja) * 2004-09-09 2011-03-30 国立大学法人東京農工大学 歯周病発症の評価システム
CN101111288A (zh) * 2004-12-02 2008-01-23 高露洁-棕榄公司 含酚类化合物和抗氧化剂维生素和维生素衍生物的口腔护理组合物
US20060141421A1 (en) 2004-12-28 2006-06-29 Kimberly-Clark Worldwide, Inc. System and method for detecting substances related to oral health
WO2006074450A2 (en) 2005-01-07 2006-07-13 President And Fellows Of Harvard College Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
JP5024506B2 (ja) * 2005-03-25 2012-09-12 ライオン株式会社 歯周組織破壊の抑制・改善剤及び口腔用組成物
RU2431845C2 (ru) 2006-01-10 2011-10-20 Колгейт-Палмолив Компани Способы модулирования рецепторов клеточных поверхностей для предотвращения или снижения воспаления
US20080161394A1 (en) 2006-11-23 2008-07-03 Jean-Yves Fouron Cosmetic composition comprising at least one volatile carbonic acid ester
WO2008093072A2 (en) 2007-01-29 2008-08-07 Paul Webb Topical composition against contact dermatitis due to water
US8333981B2 (en) 2007-10-09 2012-12-18 Humco Holding Group, Inc. Antifungal treatment of nails
TWI481870B (zh) * 2009-04-01 2015-04-21 Colgate Palmolive Co 用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記

Also Published As

Publication number Publication date
TW201039812A (en) 2010-11-16
MY158406A (en) 2016-10-14
CN102365550A (zh) 2012-02-29
PL2414838T3 (pl) 2014-01-31
EP2414838A1 (en) 2012-02-08
RU2011144028A (ru) 2013-05-10
US20120107843A1 (en) 2012-05-03
AU2010232590A1 (en) 2011-08-18
WO2010115031A1 (en) 2010-10-07
DK2414838T3 (da) 2013-11-04
EP2414838B1 (en) 2013-08-28
JP2012524884A (ja) 2012-10-18
CA2757317C (en) 2014-03-11
CA2757317A1 (en) 2010-10-07
HK1167272A1 (en) 2012-11-23
BRPI1013185A2 (pt) 2016-04-12
CO6420374A2 (es) 2012-04-16
TWI405565B (zh) 2013-08-21
ZA201106054B (en) 2014-01-29
JP5330596B2 (ja) 2013-10-30
SG173487A1 (en) 2011-09-29
CN102365550B (zh) 2014-08-13
RU2524629C2 (ru) 2014-07-27
MX2011008438A (es) 2011-09-06
ES2432864T3 (es) 2013-12-05
AU2010232590B2 (en) 2013-03-07
US8637266B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
Brockhaus et al. α-Neurexins together with α2δ-1 auxiliary subunits regulate Ca2+ influx through Cav2. 1 channels
Vemu et al. Severing enzymes amplify microtubule arrays through lattice GTP-tubulin incorporation
Haberlandt et al. Gray matter NG2 cells display multiple Ca2+-signaling pathways and highly motile processes
Talpalar et al. Dual-mode operation of neuronal networks involved in left–right alternation
Scott et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value
BR112015004881A2 (pt) método para diagnosticar o estado da doença periodontal e kit para diagnosticar o estado da doença periodontal
Boyd et al. Cortical feedback control of olfactory bulb circuits
Di Cristo et al. Activity-dependent PSA expression regulates inhibitory maturation and onset of critical period plasticity
Sokolow et al. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
Shen et al. GABAergic control of critical developmental periods for anxiety-and depression-related behavior in mice
CR10438A (es) Celulas madre adultas derivadas de tejido adiposo utilizadas en la regeneracion hepatica
ATE452343T1 (de) Verbesserte vitamin-d-messung
MX345316B (es) Métodos y composiciones para diagnóstico y tratamiento del cáncer.
AR076177A1 (es) MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
Fernandes et al. Hydrogen sulfide plays a key role in the inhibitory neurotransmission to the pig intravesical ureter
Goto et al. Dynamics of pulsatile activities of arcuate kisspeptin neurons in aging female mice
MX2022001898A (es) Metodos para el tratamiento de enfermedades asociadas a la senescencia.
Hutcheson et al. Elastogenesis correlates with pigment production in murine aortic valve leaflets
PE20220003A1 (es) Metodo para la prediccion de eficacia del tratamiento de hemoglobinopatia
ATE478335T1 (de) Verfahren in echtzeit zur erkennung von akuten entzündungszuständen
Li et al. Macrophage M2 polarization promotes pulpal inflammation resolution during orthodontic tooth movement
EP2298866A4 (en) ARTIFICIAL KIDNEY PROCESSORS AND MANUFACTURING METHOD THEREFOR
JP2012524884A5 (enExample)

Legal Events

Date Code Title Description
FB Suspension of granting procedure